ProSight: a Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population

Launched by SHANGHAI WEIHE MEDICAL LABORATORY CO., LTD. · Jan 16, 2025

Keywords

ClinConnect Summary

The ProSight trial is a study aimed at finding out if a blood test can help detect several types of cancer, such as lung, colorectal, liver, gastric, and esophageal cancers, in people who do not show any symptoms. The goal is to see if this test, which checks for signs of cancer early, can be used for screening adults aged 40 to 74. This study will take place at multiple locations and is not yet recruiting participants.

To participate in this trial, you need to be between 40 and 74 years old and be able to give your consent to take part in the study. However, if you have had any recent signs of cancer, are currently undergoing treatment for cancer, or have certain medical conditions like autoimmune diseases, you may not be eligible. If you join the trial, you can expect to provide a blood sample for testing, and the researchers will guide you through the process and any necessary procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 40-74 years old
• • Able to provide a written informed consent and willing to comply with all parts of the protocol procedures
• Exclusion Criteria:
• • With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen
• • Have definite contraindications of cancer screening examination and diagnostic procedures
• • Unable to comply with the protocol procedures
• • Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date
• • Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrinotherapy for cancer is not an exclusion criterion.
• • Recipients of anti-tumor therapy within 30 days prior to screen
• • Pregnancy or lactating women
• • Recipients of organ transplant or prior bone marrow transplant or stem cell transplant
• • Recipients of blood transfusion within 7 days prior to screen
• • With autoimmune diseases
• • Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw
• • Unsuitable for this trial determined by the researchers (eg. hemorrhagic diseases)